Drugs · acquisition-cost intelligence
Clindamycin Phosphate
clindamycin phosphate· ingredient clindamycinAntibiotics· CLINDAMYCIN PHOSPHATE 10 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$0.13710
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other clindamycin products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| Cleocin Pediatric | $0.14112 | +$0.00400 |
| Clindamycin HCL | $0.17586 | +$0.03880 |
| Cleocin Hydrochloride | $0.17586 | +$0.03880 |
| Cleocin T | $0.18000 | +$0.04290 |
| Clindacin P | $0.20298 | +$0.06590 |
| Cleocin | $1.79 | +$1.66 |
| Clindacin | $2.31 | +$2.17 |
| Clindagel | $4.02 | +$3.88 |
Medicare Part D coverage · CY2026
On 246 plan formularies · typical tier 3
Prior auth 0% · Step therapy 0% · Quantity limit 62% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.